Serum Metabolomics Benefits Discrimination Kidney Disease Development in Type 2 Diabetes Patients.

Peng, Xiaofeng; Wang, Xiaoyi; Shao, Xue; Wang, Yucheng; Feng, Shi; Wang, Cuili; Ye, Cunqi; Chen, Jianghua; Jiang, Hong

Peng, Xiaofeng; Wang, Xiaoyi; Shao, Xue; Wang, Yucheng; Feng, Shi; Wang, Cuili; Ye, Cunqi; Chen, Jianghua; Jiang, Hong.

Afiliação

Peng X; Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Wang X; Key Laboratory of Kidney Disease Prevention and Control Technology, Hangzhou, China.
Shao X; Institute of Nephropathy, Zhejiang University, Hangzhou, China.
Wang Y; Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, China.
Feng S; Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Wang C; Key Laboratory of Kidney Disease Prevention and Control Technology, Hangzhou, China.
Ye C; Institute of Nephropathy, Zhejiang University, Hangzhou, China.
Chen J; Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, China.
Jiang H; Department of Nephrology, The First Affiliated Hospital of Huzhou Teachers College, The First People's Hospital of Huzhou, Huzhou, China.

Front Med (Lausanne) ; 9: 819311, 2022.

Article em En | MEDLINE | ID: mdl-35615098

Palavras-chave

biomarker discovery; diabetic kidney disease; metabolomics; progression; proteinuria

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Med (Lausanne) Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google